

**Sileo Pharmaceuticals Limited**  
**Statement of Cash Flows**  
**For the period ended March 31, 2020**

Particulars	Amount in Taka	
	01/07/2019 to 31/03/2020	01/07/2018 to 31/03/2019
<b>A. Cash Flows from Operating Activities</b>		
Cash received from Customers	588,101,409	565,936,084
Cash received from Non-operating income	8,123,614	292,168
Cash Paid to Suppliers	(316,488,327)	(428,872,877)
Cash Paid to Employees	(69,702,514)	(82,071,405)
Cash Paid to Others	(81,430,051)	(47,087,049)
Income Tax Paid	(1,753,189)	(866,505)
<b>Net cash flows from operating activities</b>	<b>126,850,941</b>	<b>7,330,415</b>
<b>B. Cash Flows from Investing Activities</b>		
Acquisition of Property, Plant & Equipment	(36,310,000)	(412,375)
Cash Payments for Capital Work-in-Progress	(110,122,157)	(6,049,050)
<b>Net cash flows from investing activities</b>	<b>(146,432,157)</b>	<b>(6,461,425)</b>
<b>C. Cash Flows from Financing Activities</b>		
Cash Dividend paid	(18,874,000)	-
Net Received/(Payment) in Long Term Loan	-	(7,326,431)
Refund to IPO Applicants	(1,957,990)	-
<b>Net Cash flows from financing activities</b>	<b>(20,831,990)</b>	<b>(7,326,431)</b>
<b>D. Net Increase/(Decrease) Cash and Cash Equivalents (A+B+C)</b>	<b>(40,413,206)</b>	<b>(6,457,440)</b>
<b>E. Opening Cash and Cash Equivalents</b>	<b>301,719,359</b>	<b>17,675,005</b>
<b>F. Closing Cash and Cash Equivalents (D+E)</b>	<b>261,306,153</b>	<b>11,217,564</b>
<b>Net Operating Cash Flows Per Share (NOCFPS)</b>	<b>1.22</b>	<b>0.10</b>







Chief Financial Officer    Company Secretary    Managing Director    Director    Chairman

Place: Dhaka  
Date: June 29, 2020

**Silco Pharmaceuticals Limited**  
**Statement of Changes in Equity**  
**For the period ended March 31, 2020**

*(Amount in Taka)*



Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as at July 01, 2019	943,700,000	1,238,497,715	2,182,197,715
Issue of Share Capital (Bonus 10%)	94,370,000	(94,370,000)	-
Dividend (Cash 2%)		(18,874,000)	(18,874,000)
Net Profit during the period	-	78,939,608	78,939,608
<b>Balance as on March 31, 2020</b>	<b>1,038,070,000</b>	<b>1,204,193,322</b>	<b>2,242,263,322</b>

**Statement of Changes in Equity**  
**For the period ended March 31, 2019**

*(Amount in Taka)*

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as at July 01, 2018	643,700,000	992,012,653	1,635,712,653
Net Profit during the period	-	78,304,552	78,304,552
<b>Balance as on March 31, 2019</b>	<b>643,700,000</b>	<b>1,070,317,205</b>	<b>1,714,017,205</b>




Chief Financial Officer    Company Secretary    Managing Director    Director    Chairman

Place: Dhaka  
 Date: June 29, 2020


**Sileo Pharmaceuticals Limited**  
**Statement of Profit or Loss and other Comprehensive Income**  
**For the period ended March 31, 2020**

Particulars	Notes	Amount in Taka		Quarterly Result	
		01/07/2019 to	01/07/2018 to	01/01/2020 to	01/01/2019 to
		31/03/2020	31/03/2019	31/03/2020	31/03/2019
Sales Revenue	16.00	602,438,731	707,697,127	198,865,438	240,878,442
Less: Cost of Goods Sold	17.00	411,853,540	484,654,942	133,415,461	159,282,955
<b>Gross Profit</b>		<b>190,585,191</b>	<b>223,042,185</b>	<b>65,449,977</b>	<b>81,595,487</b>
Less: Operating Expenses	18.00	87,232,806	95,419,975	28,987,755	32,166,412
<b>Profit from Operation</b>		<b>103,352,385</b>	<b>127,622,210</b>	<b>36,462,223</b>	<b>49,429,075</b>
Less: Financial Expenses	19.00	960,548	727,676	220,450	227,967
Add: Non-operation Income	20.00	8,123,614	150,360	54,210	47,105
<b>Profit before Contribution to WPPF</b>		<b>100,515,451</b>	<b>127,044,894</b>	<b>36,295,983</b>	<b>49,248,212</b>
Less: Workers' Profit Participation/Welfare Fund		5,262,641	6,049,757	1,728,380	2,345,153
<b>Profit before Tax</b>		<b>105,252,810</b>	<b>120,995,137</b>	<b>34,567,602</b>	<b>46,903,059</b>
Less: Income Tax Expenses	21.00	26,313,203	42,348,298	8,641,901	16,416,071
Current Tax		22,986,055	34,856,070	7,551,918	13,959,222
Deferred Tax		3,327,148	7,492,228	1,089,982	2,456,849
<b>Net Profit after Tax</b>		<b>78,939,608</b>	<b>78,646,839</b>	<b>25,925,702</b>	<b>30,486,989</b>
<b>Earnings per Share (EPS)</b>	22.00	<b>0.76</b>	<b>1.07</b>	<b>0.25</b>	<b>0.41</b>


The annexed notes form an integral part of these financial

  
 Chief Financial Officer

  
 Company Secretary

  
 Managing Director

  
 Director

  
 Chairman

Place: Dhaka  
 Date: June 29, 2020

**Sileo Pharmaceuticals Limited**  
**Statement of Financial Position**  
**As at March 31, 2020**

Particulars		Amount in Taka	
		31 March 2020	30 June 2019
<b>Assets</b>			
<b>Non Current Assets</b>		<b>1,330,100,369</b>	<b>1,242,539,972</b>
Property, Plant & Equipment	3.00	1,100,242,919	1,122,804,679
Capital Work in Progress	4.00	229,857,450	119,735,293
<b>Current Assets</b>		<b>1,328,115,820</b>	<b>1,325,733,939</b>
Inventories	5.00	448,500,348	426,025,690
Trade Receivables	6.00	504,324,046	489,986,724
Advance, Deposits and Prepayments	7.00	113,985,273	108,002,166
Cash and Cash Equivalents	8.00	261,306,153	301,719,359
<b>Total Assets</b>		<b>2,658,216,191</b>	<b>2,568,273,912</b>
<b>Shareholders Equity and Liabilities</b>			
<b>Shareholders Equity</b>		<b>2,242,263,322</b>	<b>2,182,197,715</b>
Share Capital	9.00	1,038,070,000	943,700,000
Retained Earnings	10.00	1,204,193,322	1,238,497,715
<b>Non-Current Liabilities</b>		<b>150,774,399</b>	<b>147,447,251</b>
Deferred Tax Liability	11.00	150,774,399	147,447,251
<b>Current Liabilities</b>		<b>265,178,469</b>	<b>238,628,946</b>
Trade Payable	12.00	16,402,679	15,717,627
Payable to IPO Applicants		185,020	2,143,010
Creditors & Accruals	13.00	12,503,227	12,929,461
Liability for WPPF	14.00	12,352,516	7,089,876
Current Tax Liability	15.00	223,735,026	200,748,972
<b>Total Shareholders Equity and Liabilities</b>		<b>2,658,216,190</b>	<b>2,568,273,912</b>
<b>Net Asset Value (NAV) per Share</b>		<b>21.60</b>	<b>23.12</b>

The annexed notes form an integral part of these financial statements.

 Chief Financial Officer	 Company Secretary	 Managing Director	 Director	 Chairman
--	---	--	---	---

Place: Dhaka  
Date: June 29, 2020